Saturday 17 October 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 53.3%, free cash flow fell 66.6% and total debt fell 97.9%, each against the same quarter a year earlier.
18.16
0.65
−3.46%
Follow GHRS
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 4.85 | 24.03 | 101.80 | 37.07 | 24.49 | 17.23 | 34.13 |
Net Debt/EBITDA |
— | 1.61 | 13.22 | 18.35 | 5.44 | 3.93 | 2.98 | 4.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.28% | 0.20% | 0.05% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.93 | 0.74 | 1.66 | 1.17 | 0.94 | 1.09 | 0.90 |
Capex/Depreciation |
— | — | — | (5.47) | (1.43) | (0.32) | (0.16) | (0.36) |
Interest Coverage |
— | — | — | (1,677.78) | (248.41) | (57.02) | (70.17) | (131.14) |
| — | (10.34%) | (14.70%) | (6.51%) | (8.52%) | (15.18%) | (19.58%) | (21.04%) | |
| — | (123.02%) | (13.90%) | (6.44%) | (8.41%) | (14.81%) | (18.80%) | (20.26%) | |
ROIC |
— | 0.00% | 0.00% | (2,365.29%) | (22.77%) | (44.39%) | (104.83%) | 0.00% |
Return on Tangible Assets |
— | (77.50%) | (7.87%) | (3.32%) | (13.69%) | (22.46%) | (26.68%) | (17.35%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | (0.01) | (0.35) | (0.50) | (0.64) | (0.81) | (0.72) |
Cash per Share |
— | 0.01 | 0.21 | 6.34 | 3.19 | 3.11 | 2.87 | 4.60 |
Shareholders Equity per Share |
— | 0.01 | 0.20 | 6.35 | 4.80 | 4.21 | 3.44 | 4.58 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.01 | 0.20 | 6.35 | 4.80 | 4.21 | 3.44 | 4.58 |
Free Cash Flow |
— | (0.29) | (0.33) | (15.39) | (26.27) | (33.44) | (42.33) | (43.67) |
Working Capital |
— | 0.40 | 5.67 | 277.09 | 164.00 | 157.39 | 145.27 | 277.60 |
Capital Expenditures |
— | — | — | (0.10) | (0.07) | (0.10) | (0.05) | (0.12) |
Net Current Asset Value |
— | 0.40 | 5.67 | 277.09 | 164.00 | 156.76 | 144.90 | 277.45 |
| Other line items | ||||||||
Quick Ratio |
— | 4.79 | 23.96 | 100.68 | 36.51 | 24.11 | 16.68 | 33.50 |
Depreciation/Fixed assets |
— | — | — | 0.23 | 0.48 | 0.29 | 0.42 | 0.54 |
Cash ROIC |
— | (32.18%) | (2.85%) | (2.78%) | (6.32%) | (8.77%) | (12.88%) | (7.79%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | (0.01) | (0.35) | (0.50) | (0.64) | (0.81) | (0.71) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | 0.07 | — | — | — |
Average Payables |
— | 0.05 | 0.05 | 0.44 | 1.38 | 2.68 | 3.62 | 3.76 |
Average Assets |
— | 0.25 | 3.21 | 142.92 | 267.14 | 240.33 | 207.29 | 238.25 |
Average Common Equity |
— | 3.00 | 3.03 | 141.42 | 263.50 | 234.39 | 198.96 | 229.33 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates